Sesen Bio obtains final court approval for derivative lawsuit settlement

Carisma Therapeutics Inc.

U.S. District Court for Massachusetts granted final approval on Nov 8, 2022 for settlement of consolidated derivative lawsuits.
Settlement covers In re Sesen Bio, Inc. Derivative Litigation, Lead Case No. 1:21-cv-11538, and Tang v. Sesen Bio, Inc., Case No. 2281-cv-00135.
Company also disclosed securities class action settlement hearing set for Jan 23, 2023 in Southern District of New York.
Previously, court granted preliminary approval on Sep 2, 2022; terms in Aug 30, 2022 8-K.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.